GO:0031696 alpha-2C adrenergic receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031696 alpha-2C adrenergic receptor binding is a molecular function defined as binding to an alpha-2C adrenergic receptor (ADRA2C).
• The alpha-2C adrenergic receptor is one of three alpha-2 adrenergic receptor subtypes (alpha-2A, alpha-2B, alpha-2C) that mediate responses to catecholamines.
• Alpha-2C adrenergic receptor binding is involved in presynaptic autoinhibition of neurotransmitter release and in central nervous system functions.
• The alpha-2C subtype shows distinct pharmacological properties and down-regulation behavior compared to other alpha-2 subtypes.
• Temperature-sensitive trafficking of the alpha-2C adrenergic receptor is modulated by HSP90, affecting receptor availability at the cell surface.
• The alpha-2C adrenergic receptor is a target for PET imaging ligands such as [11C]ORM-13070, enabling in vivo occupancy studies.
Description
GO:0031696 alpha-2C adrenergic receptor binding describes the molecular function of selectively interacting with the alpha-2C adrenergic receptor (ADRA2C), a G protein-coupled receptor that responds to catecholamines such as norepinephrine and epinephrine. This binding event is fundamental to understanding how endogenous ligands, synthetic agonists, antagonists, and imaging tracers modulate alpha-2C receptor activity in physiological and pathological contexts. The alpha-2C subtype is one of three closely related alpha-2 adrenergic receptors (alpha-2A, alpha-2B, alpha-2C) that share significant sequence homology but exhibit distinct tissue distribution and pharmacological profiles. Researchers study alpha-2C adrenergic receptor binding to dissect subtype-specific signaling, to develop selective therapeutics for neurological and psychiatric disorders, and to design PET ligands for receptor occupancy imaging. The term is also relevant for understanding off-target effects of adrenergic drugs and for interpreting ligand-receptor docking studies. Given the clinical importance of adrenergic signaling, precise characterization of alpha-2C binding interactions remains an active area of molecular pharmacology and drug discovery.
alpha-2C adrenergic receptor binding At A Glance
| GO ID | GO:0031696 |
|---|---|
| GO term | alpha-2C adrenergic receptor binding |
| Ontology | molecular_function |
| Synonym | alpha-2C adrenergic receptor ligand |
| Major function | Binding to the alpha-2C adrenergic receptor (ADRA2C), a G protein-coupled receptor for catecholamines |
| Related receptor | ADRA2C (alpha-2C adrenergic receptor) |
| Subtype family | Alpha-2 adrenergic receptors (alpha-2A, alpha-2B, alpha-2C) |
| Endogenous ligands | Norepinephrine, epinephrine |
| Research tools | Selective agonists/antagonists, PET ligands (e.g., [11C]ORM-13070) |
What Is GO:0031696?
In simple terms, GO:0031696 alpha-2C adrenergic receptor binding is the function of a molecule (such as a drug, hormone, or protein) physically attaching to the alpha-2C adrenergic receptor. According to the QuickGO definition, it is the binding to an alpha-2C adrenergic receptor. This molecular function is a subtype-specific interaction that distinguishes alpha-2C from other adrenergic receptor subtypes.
Why Is alpha-2C adrenergic receptor binding Important in Cell Biology?
Alpha-2C adrenergic receptor binding is critically important because it governs subtype-specific modulation of neurotransmitter release, cardiovascular function, and central nervous system activity. Dysregulation of alpha-2C receptor binding has been implicated in conditions such as hypertension, depression, and neurodegenerative disorders, making it a target for drug development. Additionally, the unique temperature-sensitive trafficking of the alpha-2C receptor, regulated by HSP90, highlights how binding interactions can be influenced by cellular chaperones. Understanding this binding function also aids in the design of selective PET ligands for imaging receptor occupancy in vivo, which is essential for clinical translation.
• Alpha-2C adrenergic receptor binding mediates presynaptic autoinhibition of norepinephrine release, affecting sympathetic tone.
• The alpha-2C subtype is involved in central nervous system functions such as sedation, analgesia, and regulation of mood.
• Selective alpha-2C binding is a target for developing drugs for hypertension, depression, and attention deficit hyperactivity disorder.
• Alpha-2C receptor binding is studied using PET ligands like [11C]ORM-13070 for non-invasive imaging of receptor occupancy.
• Differential down-regulation of alpha-2C compared to other subtypes affects long-term drug responses.
• HSP90 modulates temperature-sensitive trafficking of alpha-2C, influencing binding site availability.
• Molecular docking studies of melatonin-alpha adrenergic receptor complexes provide insights into binding interactions.
• Crystal structures of related adrenergic receptors (e.g., alpha-1B) reveal determinants of selective ligand recognition.
• Alpha-2C binding is relevant for understanding off-target effects of adrenergic medications.
• The alpha-2C receptor is a potential target for treating neurodegenerative diseases due to its role in neuroprotection.
Molecular Mechanism of alpha-2C adrenergic receptor binding
Ligand Recognition and Binding Pocket
In simple terms: The alpha-2C receptor has a specific pocket where catecholamines and drugs can fit and bind.
The alpha-2C adrenergic receptor (ADRA2C) belongs to the class A family of G protein-coupled receptors (GPCRs) and contains a canonical orthosteric binding pocket formed by transmembrane helices. Endogenous ligands such as norepinephrine and epinephrine bind to this pocket through interactions with conserved aspartate and serine residues, leading to receptor activation. Selective synthetic ligands can discriminate between alpha-2 subtypes based on subtle differences in the binding pocket, as revealed by pharmacological characterization. Crystal structures of related adrenergic receptors, such as the alpha-1B adrenergic receptor, have elucidated molecular determinants of selective ligand recognition that can be extrapolated to alpha-2C.
G Protein Coupling and Signal Transduction
In simple terms: Once a ligand binds, the receptor activates G proteins that trigger downstream signaling.
Binding of agonists to the alpha-2C adrenergic receptor induces conformational changes that promote coupling to Gi/Go proteins, inhibiting adenylyl cyclase and reducing cAMP levels. This signaling cascade mediates presynaptic inhibition of neurotransmitter release and other cellular responses. The alpha-2C subtype exhibits distinct coupling efficiency and regulatory properties compared to alpha-2A and alpha-2B, which contributes to subtype-specific physiology. Differential down-regulation of alpha-2 subtypes upon prolonged agonist exposure further modulates signaling output.
Regulation by Chaperones and Trafficking
In simple terms: Chaperone proteins like HSP90 control how the receptor moves inside the cell and reaches the surface.
The alpha-2C adrenergic receptor displays unusual temperature-sensitive trafficking, and its maturation and cell surface expression are modulated by the chaperone HSP90. HSP90 inhibition alters the intracellular transport of alpha-2C, affecting the availability of binding sites at the plasma membrane. This regulation is unique among adrenergic receptor subtypes and impacts the interpretation of binding assays performed at different temperatures. Such chaperone-dependent trafficking adds a layer of complexity to alpha-2C receptor binding studies.
Pharmacological Modulation and Subtype Selectivity
In simple terms: Drugs can be designed to bind only to alpha-2C, avoiding other subtypes.
Pharmacological characterization has identified agonists and antagonists with varying selectivity for alpha-2C over alpha-2A and alpha-2B. Selective ligands are valuable tools for dissecting alpha-2C-specific functions in vivo and for developing therapeutics with fewer side effects. PET ligands such as [11C]ORM-13070 have been evaluated for their ability to bind alpha-2C receptors in non-human primates, enabling occupancy studies. Molecular docking analyses of melatonin-alpha adrenergic receptor complexes provide additional insights into ligand-receptor interactions that can guide drug design.
Allosteric and Modulatory Interactions
In simple terms: Other molecules can bind outside the main pocket and change how the receptor works.
Beyond orthosteric binding, allosteric modulators can influence alpha-2C receptor function by binding to distinct sites and altering ligand affinity or efficacy. The binding of accessory proteins, such as arrestins, also regulates receptor desensitization and internalization. Understanding these modulatory interactions is essential for comprehensive models of alpha-2C adrenergic receptor binding and its physiological consequences.
Key Genes Involved in GO:0031696 alpha-2C adrenergic receptor binding
The following genes and proteins are directly involved in or interact with alpha-2C adrenergic receptor binding, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRA2C | Encodes the alpha-2C adrenergic receptor, the primary binding target | Central to all studies of GO:0031696; target for selective ligands and PET imaging |
| ADRA2A | Encodes alpha-2A adrenergic receptor, a related subtype | Used for comparative pharmacology and subtype selectivity studies |
| ADRA2B | Encodes alpha-2B adrenergic receptor, a related subtype | Serves as a reference for subtype-specific binding and down-regulation |
| HSP90AA1 | Chaperone protein that modulates alpha-2C trafficking | Regulates temperature-sensitive maturation and surface expression of ADRA2C |
| GNAI1 | Gi protein alpha subunit, couples to alpha-2C | Mediates downstream signaling upon agonist binding |
| GNAO1 | Go protein alpha subunit, couples to alpha-2C | Alternative G protein coupling for alpha-2C in neurons |
| ARRB1 | Beta-arrestin 1, involved in receptor desensitization | Regulates internalization and recycling of alpha-2C after binding |
| ARRB2 | Beta-arrestin 2, involved in receptor desensitization | Modulates alpha-2C signaling and trafficking |
| ADRA1B | Alpha-1B adrenergic receptor, structurally related | Crystal structure provides insights into ligand recognition determinants |
| ORM-13070 | Selective alpha-2C PET ligand (not a gene) | Used for in vivo occupancy imaging of alpha-2C |
| Melatonin receptor (MT1/MT2) | Interacts with alpha adrenergic receptors | Studied in docking complexes with alpha adrenergic receptors |
| 3-iodothyronamine | Endogenous amine that modulates adrenergic signaling | Differentially modulates alpha-2A-mediated signaling, relevant for subtype comparison |
| Norepinephrine | Endogenous catecholamine ligand | Primary physiological agonist for alpha-2C binding |
| Epinephrine | Endogenous catecholamine ligand | Binds alpha-2C with lower affinity than norepinephrine |
| Yohimbine | Classical alpha-2 antagonist | Used as a reference ligand in binding assays |
| Clonidine | Alpha-2 agonist | Used to study alpha-2C-mediated effects |
| RX821002 | Selective alpha-2 antagonist radioligand | Commonly used in receptor binding assays |
| UK-14,304 | Alpha-2 agonist | Used for pharmacological characterization of alpha-2 subtypes |
How Is alpha-2C adrenergic receptor binding Regulated?
The binding function of alpha-2C adrenergic receptors is regulated at multiple levels. Receptor expression and trafficking are modulated by the chaperone HSP90, which affects temperature-sensitive maturation and cell surface availability. Prolonged agonist exposure leads to differential down-regulation of alpha-2 subtypes, with alpha-2C showing distinct regulatory kinetics compared to alpha-2A and alpha-2B. Additionally, post-translational modifications such as phosphorylation by G protein-coupled receptor kinases (GRKs) and subsequent beta-arrestin recruitment regulate receptor desensitization and internalization. These regulatory mechanisms collectively control the number of available binding sites and the duration of signaling, which are critical for physiological responses and drug efficacy.
alpha-2C adrenergic receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADRA2C | Hypertension | ADRA2C knockout mouse, overexpression cell lines |
| ADRA2C | Depression / anxiety | ADRA2C knockout mouse, behavioral assays |
| ADRA2C | Neurodegeneration | ADRA2C knockout and knock-in models, neurotoxicity assays |
| HSP90AA1 | Cancer (chaperone-related) | HSP90 inhibitor treatment in ADRA2C-expressing cells |
| ADRA2C | PET imaging of receptor occupancy | Non-human primate PET with [11C]ORM-13070 |
Alpha-2C adrenergic receptor binding in cardiovascular disease
Alpha-2 adrenergic receptors, including the alpha-2C subtype, play key roles in regulating vascular tone and cardiac function. Altered alpha-2C binding and signaling have been associated with hypertension and other cardiovascular disorders, making the receptor a potential therapeutic target. Selective ligands that modulate alpha-2C binding could offer new strategies for blood pressure control with fewer central side effects.
Alpha-2C adrenergic receptor binding in neuropsychiatric disorders
In the central nervous system, alpha-2C adrenergic receptors are involved in modulating neurotransmitter release, sedation, and mood. Dysregulation of alpha-2C binding has been implicated in depression, anxiety, and attention deficit hyperactivity disorder. PET imaging studies using ligands such as [11C]ORM-13070 enable non-invasive assessment of alpha-2C receptor occupancy in the brain, facilitating drug development for these conditions.
Alpha-2C adrenergic receptor binding in neurodegeneration
The alpha-2C adrenergic receptor has been studied in the context of neurodegenerative diseases due to its role in neuroprotection and modulation of neuroinflammation. Changes in alpha-2C binding affinity or density may contribute to disease progression, although the exact mechanisms remain under investigation. The unique trafficking regulation of alpha-2C by HSP90 may also influence neuronal vulnerability.
Alpha-2C adrenergic receptor binding as a drug target
The alpha-2C subtype is a target for drug discovery, with efforts focused on developing selective agonists and antagonists for various indications. Molecular docking studies of melatonin-alpha adrenergic receptor complexes provide structural insights that can guide the design of novel ligands. Additionally, the crystal structure of the related alpha-1B adrenergic receptor has revealed molecular determinants of selective ligand recognition that may inform alpha-2C-selective drug design.
From alpha-2C adrenergic receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ADRA2C mediate presynaptic autoinhibition? | ADRA2C knockout mouse |
| How does alpha-2C binding affect cardiovascular function? | ADRA2C knockout rat or mouse, telemetry |
| What is the role of HSP90 in alpha-2C trafficking? | HSP90 knockdown or inhibition in ADRA2C-expressing cells |
| Can selective alpha-2C ligands be developed? | Point mutations in ADRA2C binding pocket, ligand binding assays |
| How does alpha-2C down-regulation compare to other subtypes? | Knock-in of ADRA2C into ADRA2A locus or vice versa |
| What is the in vivo occupancy of alpha-2C ligands? | Non-human primate PET with [11C]ORM-13070 |
How to Study the alpha-2C adrenergic receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and density of alpha-2C receptors | Pharmacological characterization of ligands |
| PET imaging | In vivo receptor occupancy | Clinical translation and drug development |
| Molecular docking | Predicted ligand binding modes | Virtual screening and drug design |
| cAMP assay | Functional activation of alpha-2C | Agonist/antagonist profiling |
| GTPγS binding | G protein activation | Intrinsic activity of ligands |
| Immunoblotting | Receptor protein levels | Down-regulation studies |
| Immunofluorescence | Subcellular localization | Trafficking studies |
| Site-directed mutagenesis | Role of specific residues in binding | Structure-function analysis |
Radioligand binding assays
Radioligand binding assays using selective alpha-2 antagonists such as [3H]RX821002 or [3H]yohimbine are standard for measuring alpha-2C adrenergic receptor binding affinity and density. These assays can be performed on membrane preparations from cells expressing recombinant ADRA2C or on tissue homogenates. Competition binding experiments with unlabeled ligands determine selectivity profiles.
PET imaging with selective ligands
Positron emission tomography (PET) using ligands like [11C]ORM-13070 allows non-invasive quantification of alpha-2C adrenergic receptor occupancy in living subjects. Preclinical evaluation in non-human primates has demonstrated the feasibility of this approach for assessing receptor availability and drug occupancy. This method is valuable for translational studies and clinical trials.
Molecular docking and structural analysis
Molecular docking studies, such as those assessing melatonin-alpha adrenergic receptor complexes, provide computational insights into ligand binding modes and affinities. Crystal structures of related adrenergic receptors, like the alpha-1B adrenergic receptor, reveal conserved and divergent features of the binding pocket that can be modeled for alpha-2C. These methods guide the design of selective ligands.
Cell-based signaling assays
Functional assays measuring cAMP inhibition or GTPγS binding are used to assess alpha-2C receptor activation upon ligand binding. These assays can be performed in cell lines expressing recombinant ADRA2C or in primary cells. They complement binding studies by linking occupancy to downstream signaling.
How CRISPR Can Be Used to Study GO:0031696 alpha-2C adrenergic receptor binding
Knockout
CRISPR knockout of ADRA2C in cell lines or animal models eliminates alpha-2C adrenergic receptor binding, allowing researchers to study its specific contribution to signaling and physiology. ADRA2C knockout mice have been used to dissect the role of this subtype in cardiovascular and neurological functions. Knockout studies help distinguish alpha-2C-specific effects from those of other alpha-2 subtypes.
Point Mutation
CRISPR-mediated point mutations can be introduced into the ADRA2C gene to alter specific amino acids in the binding pocket, enabling structure-function studies of ligand recognition. For example, mutating conserved aspartate or serine residues can reveal their roles in catecholamine binding. Such models are valuable for validating docking predictions and for designing subtype-selective drugs.
Knock-in
Knock-in of reporter tags or human ADRA2C into model organisms allows real-time tracking of receptor expression and trafficking. Tagged knock-in models can be used to study HSP90-dependent temperature-sensitive trafficking of alpha-2C. Additionally, knock-in of disease-associated variants can model human conditions related to alpha-2C binding.
Overexpression
Overexpression of ADRA2C in cell lines is commonly used for pharmacological and biochemical studies of alpha-2C adrenergic receptor binding. Stable overexpression systems provide a homogeneous source of receptor for radioligand binding assays and signaling studies. Overexpression can also be used to study down-regulation and desensitization processes.
How EDITGENE Supports alpha-2C adrenergic receptor binding Research
Researchers studying alpha-2C adrenergic receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease. EDITGENE provides comprehensive CRISPR-based services to create precise cellular and animal models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for alpha-2C adrenergic receptor binding research.
Frequently Asked Questions About alpha-2C adrenergic receptor binding
What is GO:0031696 alpha-2C adrenergic receptor binding?
GO:0031696 is a molecular function term describing the binding to an alpha-2C adrenergic receptor, a G protein-coupled receptor that responds to catecholamines.
What genes are involved in alpha-2C adrenergic receptor binding?
The primary gene is ADRA2C, which encodes the alpha-2C adrenergic receptor. Related genes include ADRA2A, ADRA2B, and HSP90AA1.
What is the function of alpha-2C adrenergic receptor binding?
It mediates presynaptic autoinhibition of neurotransmitter release, modulates cardiovascular function, and is involved in central nervous system activities.
How is alpha-2C adrenergic receptor binding studied?
Common methods include radioligand binding assays, PET imaging with selective ligands, molecular docking, and cell-based signaling assays.
What diseases are associated with alpha-2C adrenergic receptor binding?
It has been implicated in hypertension, depression, anxiety, and neurodegenerative disorders.
What is the role of HSP90 in alpha-2C adrenergic receptor binding?
HSP90 modulates the temperature-sensitive trafficking of the alpha-2C receptor, affecting its maturation and cell surface expression.
Can alpha-2C adrenergic receptor binding be imaged in vivo?
Yes, PET ligands such as [11C]ORM-13070 have been developed for imaging alpha-2C receptor occupancy in non-human primates.
How does alpha-2C differ from other alpha-2 adrenergic receptors?
Alpha-2C exhibits distinct pharmacological properties, tissue distribution, and down-regulation behavior compared to alpha-2A and alpha-2B.
What are the endogenous ligands for alpha-2C adrenergic receptor binding?
The endogenous ligands are catecholamines, primarily norepinephrine and epinephrine.
How can CRISPR be used to study alpha-2C adrenergic receptor binding?
CRISPR can create ADRA2C knockout, point mutation, knock-in, or overexpression models to dissect receptor function and ligand interactions.
Conclusion
GO:0031696 alpha-2C adrenergic receptor binding is a specific molecular function critical for understanding subtype-selective adrenergic signaling. Its study spans pharmacology, neuroscience, and cardiovascular biology, with implications for drug development and disease treatment. Advances in CRISPR-based models and PET imaging continue to illuminate the unique properties of the alpha-2C receptor, including its HSP90-dependent trafficking and distinct down-regulation. Continued research into this binding function will likely yield new therapeutic strategies targeting adrenergic receptors.
References
- 1. Civantos Calzada B et al.. 2001. Alpha-adrenoceptor subtypes.. Pharmacol Res 44(3):195-208 PMID: 11529686
- 2. Filipeanu CM et al.. 2011. Modulation of α(2C) adrenergic receptor temperature-sensitive trafficking by HSP90.. Biochim Biophys Acta 1813(2):346-57 PMID: 21145921
- 3. Heck DA et al.. 1998. Differential down-regulation of alpha-2 adrenergic receptor subtypes.. Life Sci 62(17-18):1467-72 PMID: 9585120
- 4. Borges VG et al.. 2022. Assessment of melatonin-alpha adrenergic receptor complexes by molecular docking analysis.. Braz J Biol 82:e261624 PMID: 35920463
- 5. Bylund DB. 1995. Pharmacological characteristics of alpha-2 adrenergic receptor subtypes.. Ann N Y Acad Sci 763:1-7 PMID: 7677317
- 6. Piel I et al.. 2025. Preclinical in vitro and in vivo evaluation of [(11)C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates.. J Cereb Blood Flow Metab 45(4):677-689 PMID: 39479946
- 7. Deluigi M et al.. 2022. Crystal structure of the α(1B)-adrenergic receptor reveals molecular determinants of selective ligand recognition.. Nat Commun 13(1):382 PMID: 35046410
- 8. Dinter J et al.. 2015. 3-iodothyronamine differentially modulates α-2A-adrenergic receptor-mediated signaling.. J Mol Endocrinol 54(3):205-16 PMID: 25878061
